While Eli Lilly continues to achieve significant operational milestones, its stock performance tells a different story. The pharmaceutical giant has launched a new weight-loss drug and finalized a major acquisition, yet investor sentiment has pushed shares into negative territory for the year. This divergence between corporate success and market valuation warrants a closer examination of the underlying financials.
Robust Fundamentals Amid Market Skepticism
Setting aside short-term concerns, the company’s foundational business metrics remain exceptionally strong. Eli Lilly surpassed market expectations with its final quarter 2025 results, posting revenue of $19.3 billion. Furthermore, its guidance for the 2026 fiscal year reinforces a clear growth trajectory with specific targets:
- Projected 2026 Annual Revenue: $80 to $83 billion
- Forecasted Non-GAAP Earnings Per Share: $33.50 to $35.00
- Average Analyst Price Target: Approximately $1,222
The current share price, hovering around $926, appears to be primarily digesting the impact of the recent Centessa Pharmaceuticals acquisition. Operationally, the path forward is well-defined. Key near-term catalysts include the global rollout of the Foundayo tablet and the anticipated cost coverage by the US Medicare Part D program expected in July.
Should investors sell immediately? Or is it worth buying Eli Lilly?
A New Contender Enters the Weight-Loss Arena
The lucrative market for weight-management medications welcomed a new competitor this week with Eli Lilly’s introduction of Foundayo. The company is pursuing an aggressive pricing strategy for the oral tablet. For paying customers, the lowest dose is priced at $149 per month, significantly undercutting the $299 monthly cost for its own injectable treatment, Zepbound.
A more substantial competitive advantage lies in the drug’s chemistry. Classified as a “small-molecule” medication, Foundayo can be manufactured far more easily and at greater scale than complex biologic injections. CEO Dave Ricks anticipates this production benefit will facilitate a rapid global launch. Corresponding regulatory applications are already underway in the United States, Japan, and the European Union.
Acquisition Sparks Investor Caution
A key factor behind the stock’s decline of over 13% since the start of the year is the company’s latest purchase. The planned acquisition of Centessa Pharmaceuticals for up to $7.8 billion secures promising pipeline assets for sleep disorders. However, market analysts have expressed reservations regarding the associated short-term debt burden and the complexities of the integration process. With the stock already trading at a forward price-to-earnings ratio of around 40, the market is currently reacting with heightened sensitivity to such financial pressures.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from April 8 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 8.
Eli Lilly: Buy or sell? Read more here...
